Back
48· Steady
Technology3h 31m ago
Medical professionals are discussing the clinical differentiation, efficacy, and safety of oral SERDs (Selective Estrogen Receptor Degraders) for ESR1-mutated ER-positive metastatic breast cancer, examining their use as monotherapy versus combination therapy.
Archive Window: 7 Days Left
Not specified
Who
Dr. Iyengar, Dr. Kaklamani, Dr. Wander, Dr. Fornier
What
Medical professionals are discussing the clinical differentiation, efficacy, and safety of oral SERDs (Selective Estrogen Receptor Degraders) for ESR1-mutated ER-positive metastatic breast cancer, examining their use as monotherapy versus combination therapy.
When
Mon, 15 Jun 2026 19:00:47 GMT · 3h 31m ago
Where
Not specified ·
Why
The discussion focuses on comparing available oral SERDs, interpreting clinical trial data (EMERALD, EMBER-3, SERENA-6), and determining optimal treatment strategies for patients with ESR1-mutated metastatic breast cancer.
The Frontline Impact
How this affects you
This discussion among medical professionals helps clarify the use of existing oral SERDs and those in development for ESR1-mutated metastatic breast cancer, which may influence future treatment guidelines and patient care decisions. The debate between monotherapy and combination therapy highlights ongoing efforts to balance efficacy with patient quality of life and manage treatment toxicities, reflecting evolving standards in cancer care.
Story chain
2 events in this thread- Technology2h 43m agoAn expert roundtable discussed the clinical challenges of managing patients with co-occurring ESR1 and PIK3CA mutations in ER+ metastatic breast cancer.Open article
- Currently Reading3h 31m agoMedical professionals are discussing the clinical differentiation, efficacy, and safety of oral SERDs (Selective Estrogen Receptor Degraders) for ESR1-mutated ER-positive metastatic breast cancer, examining their use as monotherapy versus combination therapy.